Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates in clinical practice.
A total of 1254 adult patients received PRIALT as a continuous infusion in acute and severe chronic pain trials with an exposure of 662 patient-years. The mean duration of treatment was 193 days with 173 patients (14%) treated for at least 1 year. The average final dose was 17.6 mcg/day (0.73 mcg/hr).
The most frequently reported adverse reactions (≥ 25%) in clinical trials were dizziness, nausea, confusional state and nystagmus. Slower titration of PRIALT may result in fewer serious adverse reactions and discontinuation of PRIALT for adverse reactions [see Clinical Studies (14) and Dosage and Administration (2)].
Adverse reactions during the slow titration placebo-controlled trial that occurred in 5% or greater of patients and more commonly with PRIALT than with placebo are summarized in Table 1.
Table 1. Incidence of Adverse Reactions in Slow Titration Placebo-Controlled Trial by Percent (Events That Occurred in ≥ 5% of Patients and More Commonly with PRIALT than with Placebo)MedDRA System Organ Class MedDRA Preferred term | PRIALT N=112 | Placebo N=108 |
Percentage of Patients |
Any AE | 93 | 82 |
Ear and Labyrinth Disorders | | |
Vertigo | 7 | 0 |
Eye Disorders | | |
Vision Blurred | 12 | 3 |
Gastrointestinal Disorders | | |
Diarrhea | 18 | 15 |
Nausea | 40 | 29 |
Vomiting | 16 | 14 |
General Disorders and Administration Site Conditions | | |
Asthenia | 18 | 6 |
Gait Abnormal | 14 | 2 |
Pyrexia | 5 | 3 |
Rigors | 7 | 5 |
Infections and Infestations | | |
Sinusitis | 5 | 2 |
Metabolism and Nutrition Disorders | | |
Anorexia | 6 | 2 |
Musculoskeletal and Connective Tissue Disorders | | |
Muscle Spasms | 6 | 4 |
Pain in Limb | 5 | 2 |
Nervous System Disorders | | |
Amnesia | 8 | 0 |
Ataxia | 14 | 1 |
Dizziness | 46 | 13 |
Dysarthria | 7 | 0 |
Dysgeusia | 5 | 5 |
Headache | 13 | 11 |
Memory Impairment | 7 | 1 |
Nystagmus | 8 | 0 |
Somnolence | 17 | 10 |
Tremor | 7 | 3 |
Psychiatric Disorders | | |
Anxiety | 8 | 3 |
Confusional State | 15 | 5 |
Insomnia | 6 | 9 |
Renal and Urinary Disorders | | |
Urinary Retention | 9 | 0 |
Skin and Subcutaneous Disorders | | |
Pruritis | 7 | 7 |
Sweating Increased | 5 | 6 |
Other Adverse Reactions Observed During Clinical Studies of PRIALT
The following adverse reactions assessed as related to PRIALT have been reported in 2% or greater of patients participating in the clinical studies:
EYE DISORDERS: diplopia, visual disturbance
GASTROINTESTINAL DISORDERS: abdominal pain, constipation, dry mouth, nausea aggravated
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: fall, fatigue, lethargy, edema peripheral
INVESTIGATIONS: blood creatine phosphokinase increased
METABOLISM AND NUTRITION DISORDERS: appetite decreased
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS: muscle cramp, muscle weakness, myalgia, pain in limb
NERVOUS SYSTEM DISORDERS: aphasia, areflexia, balance impaired, burning sensation, coordination abnormal, disturbance in attention, dizziness postural, dysarthria, dysgeusia, hypoaesthesia, mental impairment, paraesthesia, sedation, speech disorder
PSYCHIATRIC DISORDERS: agitation, anxiety, cognitive disorder, confusional state, depression, depression aggravated, disorientation, hallucination, hallucination auditory, hallucination visual, insomnia, irritability, mood disorder, nervousness, paranoia
RENAL AND URINARY DISORDERS: dysuria, urinary hesitation
VASCULAR DISORDERS: hypotension, orthostatic hypotension.
The following medically important adverse reactions occurred in less than 2% of patients were assessed by the clinical investigators as related to PRIALT: acute renal failure, atrial fibrillation, cerebrovascular accident, sepsis, meningitis, psychotic disorder, suicidal ideation, respiratory distress, rhabdomyolysis, electrocardiogram abnormal, stupor, loss of consciousness, clonic convulsion and grand mal convulsion. Fatal aspiration pneumonia and suicide attempt were reported in less than 1% of patients.